Wall Street analysts expect AC Immune SA (NASDAQ:ACIU) to announce $12.93 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for AC Immune’s earnings. The lowest sales estimate is $7.14 million and the highest is $18.71 million. The business is scheduled to issue its next earnings results on Friday, March 16th.
According to Zacks, analysts expect that AC Immune will report full year sales of $12.93 million for the current financial year, with estimates ranging from $11.02 million to $22.87 million. For the next year, analysts expect that the company will post sales of $25.28 million per share, with estimates ranging from $25.09 million to $25.47 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow AC Immune.
AC Immune (NASDAQ:ACIU) last announced its quarterly earnings results on Monday, November 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.04.
Several brokerages have issued reports on ACIU. Zacks Investment Research raised AC Immune from a “sell” rating to a “hold” rating in a report on Monday, October 16th. BidaskClub downgraded AC Immune from a “strong-buy” rating to a “buy” rating in a report on Friday, January 19th.
Institutional investors have recently made changes to their positions in the business. Wells Fargo & Company MN acquired a new stake in AC Immune during the 3rd quarter valued at $111,000. Janney Montgomery Scott LLC acquired a new stake in AC Immune during the 3rd quarter valued at $134,000. Goldman Sachs Group Inc. acquired a new stake in shares of AC Immune during the second quarter worth $127,000. Finally, Belpointe Asset Management LLC acquired a new stake in shares of AC Immune during the third quarter worth $571,000. 17.12% of the stock is owned by institutional investors and hedge funds.
Shares of AC Immune (ACIU) traded down $0.60 during trading on Wednesday, reaching $12.63. The company’s stock had a trading volume of 63,910 shares, compared to its average volume of 65,971. AC Immune has a fifty-two week low of $6.03 and a fifty-two week high of $13.91. The firm has a market cap of $684.53 and a P/E ratio of -17.79.
TRADEMARK VIOLATION WARNING: “Brokerages Anticipate AC Immune SA (ACIU) Will Announce Quarterly Sales of $12.93 Million” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/03/brokerages-anticipate-ac-immune-sa-aciu-will-announce-quarterly-sales-of-12-93-million.html.
AC Immune Company Profile
AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms.
Get a free copy of the Zacks research report on AC Immune (ACIU)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.